Investor Relations
PrecisionPro BioTech Inc. is transforming prostate cancer diagnostics in Canada through AI-powered robotic technology. As the exclusive Canadian distributor of Biobot Surgical’s FDA- and CE-approved iSR’obot™ Mona Lisa system, we’re uniquely positioned to address one of the most critical—and underserved—needs in urologic care.
With Health Canada approval secured in April 2025, and a national shift toward minimally invasive, AI-enhanced procedures, investors have a rare opportunity to back a scalable, clinically validated platform in a rapidly growing market.
📈 Why Invest in PrecisionPro BioTech?
🇨🇦 Exclusive Distribution Rights across Canada
🔁 Recurring Revenue Model from biopsy kits and service contracts
🤝 Strategic Partnerships with leading urologists and diagnostic centers
✅ Proven Global Track Record: 23,000+ procedures completed worldwide
🧠 AI-Ready Expansion for diagnostics in prostate, liver, and lung cancers
To learn more or request our investor deck, please contact [email protected]
Vision Statement
“We’re not just bringing diagnostics to Canada—we’re setting the new standard for prostate cancer detection.”
Why Choose Us?
At PrecisionPro BioTech, we’re not just distributing technology—we’re delivering a new diagnostic standard in prostate care. Here’s why healthcare leaders and investors choose us:
• First-to-Market Advantage
We are the exclusive Canadian distributor of the world’s only AI robotic system dedicated to prostate biopsies—Biobot Surgical’s iSR’obot Mona Lisa.
• AI-Powered Precision
Our platform combines robotic accuracy with advanced imaging and artificial intelligence, enabling safer, more accurate cancer detection.
• Health Canada Approved
With regulatory approval secured in April 2025, we are ready for national deployment in a high-demand, underserved market.
• Recurring Revenue Model
Our business model is built on scalable system sales, consumables, and AI-enhanced services—ensuring long-term growth.
• Trusted Clinical Leadership
Led by urologists and AI specialists, we understand the clinical realities and technical needs of modern diagnostics.
